Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07186439

Pulmonary Hypertension Screening in Scleroderma

Screening for pulmonary hypertension in scleroderma patients

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

Scleroderma is a heterogenous connective tissue disorder characterized by fibrosis of the skin, with or without internal organ involvement. The aetiology of scleroderma may involve both environmental and genetic factors. Abnormalities involving the immune system, vascular tissue and extracellular matrix have been demonstrated.

One of the major cause of mortality in patients with scleroderma is pulmonary arterial hypertension (PAH). International recommendations advise annual screening for the early detection of PAH in asymptomatic patients with scleroderma.

scleroderma is group 1 in clinical classification of pulmonary hypertension Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units (WU)), isolated post-capillary PH (PAWP >15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP >15 mmHg, PVR >2 WU) Scleroderma has an annual prevalence of one to five cases for every 1000 individuals and nearly 15 percent of all cases develop PAH. A diagnosis of PAH in Scleroderma is virtually a death sentence, with studies reporting a mortality rate of 50 per cent in the 3 years of diagnosis. Therefore, developing and implementing screening and diagnosis protocol is important in the fight against this disease. echocardiography as the leading screening tool for scleroderma -PAH. In particular, systolic pulmonary arterial pressure (sPAP) and tricuspid regurgitation velocity (TRV). Echocardiography is non invasive tool for eary screening in pulmonary hypertension according ESC-ERS guideline If the peak tricuspid regurgitation velocity (TRV) is ≤ 2.8 m/s or not measurable, and there are no other echocardiographic signs of pulmonary hypertension, the probability is low.

If the TRV is ≤ 2.8 m/s or not measurable, but other echocardiographic signs of pulmonary hypertension are present, the probability is intermediate low

If the TRV is between 2.9 and 3.4 m/s and no other signs are present, the probability is intermediate high

If the TRV is between 2.9 and 3.4 m/s and other signs are present, the probability is high.

PH probability LOW → other causes . PH probability ntermediate low → follow up Echocardiography PH probability INTERMEDIATE high or HIGH → right heart catheterization Additional echocardiographic signs suggestive of pulmonary hypertension

A: The ventricles

RV/LV basal diameter area ratio ≥1.0

Flattening of the interventricular septum (LVEI >1.1 in systole and/or diastole)

TAPSE / sPAP ratio <0.55 mm/mmHg

B: Pulmonary artery

RVOT AT <105 ms and/or mid-systolic notching

Early diastolic pulmonary regurgitation velocity >2.2 m/s

PA diameter >25 mm

RPA diameter >25 mm

C: Inferior vena cava and RA

IVC diameter >21 mm with decreased inspiratory collapse (<50% with a sniff or <20% with quiet inspiration)

RA area (end-systole) >18 cm²

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • . Inclusion criteria: aga ≥18 years confirmed diagnosis of scleroderma

Exclusion criteria

  • aga <18 years
  • patients refused to participate

Treatment and study plan

Primary outcomes

  1. Screening for pulmonary hypertension in scleroderma patients

    Time frame: baseline

    detection rate of pulmonary hypertension in scleroderma by Echocardiography

Study contacts

Contact information is provided by the study sponsor or research team.

Esraa Sayed Abdalzeaz, Resident doctor

CONTACT

[email protected]

01093243340

Gamal Mohmed Rabea, Professor

CONTACT

[email protected]

01155213224

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 22, 2025
Registry last updated
Sep 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.